Overview

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.
Phase:
Phase 1
Details
Lead Sponsor:
R-Pharm
Treatments:
Carboplatin
Epothilones